Manuel Romero-Gomez
Overview
Explore the profile of Manuel Romero-Gomez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
388
Citations
15341
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Irshad I, Alqahtani S, Ikejima K, Yu M, Romero-Gomez M, Eslam M
Ann Hepatol
. 2025 Mar;
:101896.
PMID: 40057035
Liver fibrosis is a progressive response to chronic liver diseases characterized by a wound-healing process that leads to the accumulation of fibrillary extracellular matrix (ECM) proteins in and around the...
2.
Recompensation of decompensated cirrhosis in hepatitis C patients after SVR: Prognostic implications
Sanchez-Torrijos Y, Fernandez-Alvarez P, Rosales J, Perez-Estrada C, Alanon-Martinez P, Rodriguez-Peralvarez M, et al.
J Hepatol
. 2025 Mar;
PMID: 40056934
Backgound&aims: The Baveno VII consensus introduced the term "recompensated cirrhosis," though few studies have examined its clinical relevance. We analyzed the rate and predictors of recompensation in hepatitis C (HCV)...
3.
Feng G, Targher G, Byrne C, Yilmaz Y, Wong V, Lesmana C, et al.
JHEP Rep
. 2025 Feb;
7(3):101271.
PMID: 39980749
Background & Aims: This study used the Global Burden of Disease data (2010-2021) to analyze the rates and trends of point prevalence, annual incidence, and years lived with disability (YLDs)...
4.
Younossi Z, Razavi H, Sherman M, Allen A, Anstee Q, Cusi K, et al.
Aliment Pharmacol Ther
. 2025 Feb;
PMID: 39967239
Background: The continuum of metabolic syndrome encompasses a spectrum of dysfunctions impacting obesity-linked insulin resistance, glucose homeostasis, lipid metabolism and pro-inflammatory immune responses. The global prevalence of metabolic diseases, including...
5.
Pinar-Gutierrez A, Quintana-Gallego E, Remon-Ruiz P, Pizarro A, Gonzalez-Navarro I, Jimenez-Sanchez A, et al.
J Cyst Fibros
. 2025 Feb;
PMID: 39956714
Background & Aims: Cystic fibrosis hepatobiliary involvement is a heterogeneous and systemic entity. The primary objective was to determine the prevalence of steatosis, by magnetic resonance-proton density fat fraction (MR-PDFF),...
6.
Yip T, Lee H, Lin H, Tsochatzis E, Petta S, Bugianesi E, et al.
J Hepatol
. 2025 Jan;
PMID: 39863175
Background & Aims: Current guidelines recommend a 2-step approach for risk stratification in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) with Fibrosis-4 index (FIB-4) followed by liver stiffness measurement...
7.
Castera L, Alazawi W, Bugianesi E, Caussy C, Federici M, Romero-Gomez M, et al.
Liver Int
. 2025 Jan;
45(2):e16224.
PMID: 39752213
Background And Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) and its more severe subtype, metabolic dysfunction-associated steatohepatitis (MASH), are highly prevalent and strongly associated with obesity and type 2 diabetes...
8.
Abad J, Llop E, Arias-Loste M, Burgos-Santamaria D, Martinez Porras J, Iruzubieta P, et al.
Clin Gastroenterol Hepatol
. 2024 Dec;
PMID: 39694202
Metabolic dysfunction-associated steatohepatitis(MASH) is commonly seen in biopsy proven steatotic liver disease(SLD). Life-style intervention reaching a weight loss higher than 10% promotes MASH resolution, but this goal is only achieved...
9.
Lamas-Paz A, Hionides-Gutierrez A, Guo F, Jorquera G, Moran-Blanco L, Benede-Ubieto R, et al.
JHEP Rep
. 2024 Dec;
7(1):101230.
PMID: 39659733
Background & Aims: Expression of P21, encoded by the gene, has been associated with fibrosis progression in steatotic liver disease (SLD); however, the underlying mechanisms remain unknown. In the present...
10.
Lazarus J, Alazawi W, Basuroy R, Castera L, Estulin D, Koulla Y, et al.
Ann Hepatol
. 2024 Dec;
30(1):101741.
PMID: 39631461
Introduction And Objectives: Patients increasingly use social media to share and access health-related information and experiences. This study employed social media listening to gain patient-centric insights into metabolic dysfunction-associated steatotic...